ClinicalTrials.gg

Program

tanimilast

Also written as “CHF6001 DPI”, “CHF6001” and “CHF 6001”.

Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Asthma · Bronchitis, Chronic, led by Chiesi Farmaceutici.

Furthest: phase 3, since Nov 16, 202015 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chiesi Farmaceutici150 open or runningphase 3since Nov 16, 2020Aug 23, 2012none ahead

Also a collaborator on its studies: sgs-s-a and quintiles-inc.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 23, 2012First study: phase 2 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT01730404 · 55 enrolled · Ireland, United Kingdom
  2. Sep 4, 2012Phase 2 study in AsthmaNCT01689571 · 36 enrolled · United Kingdom
  3. Jan 22, 2015Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT02386761 · 48 enrolled · United Kingdom
  4. Oct 28, 2016Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT03004495 · 36 enrolled · United Kingdom
  5. Nov 24, 2016Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT02986321 · 1,130 enrolled
  6. Dec 2, 2016Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT03004417 · 61 enrolled · United Kingdom
  7. Nov 16, 20202 phase 3 studies in Pulmonary Disease, Chronic ObstructiveNCT04636814, NCT04636801
  8. Jan 29, 2021Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT04739774 · 24 enrolled · Belgium
  9. Feb 8, 2021Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT04756960 · 8 enrolled · United Kingdom
  10. May 10, 2022Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT05373953 · 44 enrolled · Bulgaria
  11. Aug 31, 2023Phase 2 study in AsthmaNCT06029595 · 517 enrolled · Argentina, Bulgaria, Czechia and more
  12. Apr 29, 2024Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT06395610 · 24 enrolled · Bulgaria
  13. Mar 5, 2025Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT06892756 · 30 enrolled · Bulgaria
  14. Mar 10, 2025Phase 2 study in AsthmaNCT06900816 · 50 enrolled · Bulgaria

TargetBeta

“Phosphodiesterase 4 inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
RoflumilastruleAstraZenecaphase 461
apremilastruleAmgenphase 448
ensifentrineruleMerckphase 317
difamilastruleOtsukaphase 316

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06900816Asthma · Bulgaria2CompletedAug 11, 202550
NCT06892756Pulmonary Disease, Chronic Obstructive · Bulgaria1CompletedJun 20, 202530
NCT06395610Pulmonary Disease, Chronic Obstructive · Bulgaria1CompletedJun 18, 202424
NCT06029595Asthma · Argentina, Bulgaria, Czechia and more2TerminatedDec 9, 2025517
NCT05373953Pulmonary Disease, Chronic Obstructive · Bulgaria1CompletedNov 25, 202244
NCT04756960Pulmonary Disease, Chronic Obstructive · United Kingdom1CompletedApr 29, 20218
NCT04739774Pulmonary Disease, Chronic Obstructive · Belgium1CompletedApr 20, 202124
NCT04636814Pulmonary Disease, Chronic Obstructive · United States, Argentina, Austria and more3TerminatedDec 23, 20253,973
NCT04636801Pulmonary Disease, Chronic Obstructive · United States, Albania, Argentina and more3TerminatedOct 31, 20254,710
NCT03004417Pulmonary Disease, Chronic Obstructive · United Kingdom2CompletedDec 28, 201761
NCT02986321Pulmonary Disease, Chronic Obstructive2CompletedOct 4, 20171,130
NCT03004495Pulmonary Disease, Chronic Obstructive · United Kingdom1CompletedAug 201636
NCT02386761Pulmonary Disease, Chronic Obstructive · United Kingdom1CompletedMay 201548
NCT01689571Asthma · United Kingdom2CompletedApr 201336
NCT01730404Pulmonary Disease, Chronic Obstructive · Ireland, United Kingdom2CompletedOct 201355

How it is read

Names in the registry

  • “CHF6001 DPI”, 4 entries
  • “CHF6001”, 4 entries
  • “CHF 6001”, 2 entries
  • “CHF6001 1600µg”, 1 entry
  • “CHF6001 3200µg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.